Abstract Number: 2328 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in the US, EU, and other countries for treatment of adults…Abstract Number: 0365 • ACR Convergence 2023
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
Background/Purpose: Temporomandibular joint (TMJ) arthritis, a condition frequently overlooked in patients with JIA, can result in joint damage if not promptly treated. Such damage presents…Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…Abstract Number: 1039 • ACR Convergence 2023
Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study
Background/Purpose: Ultrasound (US) allows for visualization of many features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and articular cartilage damage. Additionally, US is…Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…Abstract Number: 1427 • ACR Convergence 2023
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
Background/Purpose: Involvement of weight-bearing joints in patients with PsA can be associated with reduced activities of daily living and quality of life. Upadacitinib (UPA) is…Abstract Number: 1965 • ACR Convergence 2023
Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study
Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…Abstract Number: 2196 • ACR Convergence 2023
Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
Background/Purpose: There is increasing evidence of differences between males and females in axial spondyloarthritis (axSpA), but the source is restricted to specific geographic locations or…Abstract Number: 2500 • ACR Convergence 2023
Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Background/Purpose: Suicidal ideation is more common in SLE than in other chronic diseases. Targeted interventions are needed to reduce morbidity and mortality. Bandura’s theory of…Abstract Number: 0368 • ACR Convergence 2023
Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients
Background/Purpose: Pain trajectories vary in JIA, with some patients developing chronic pain over the course of their illness. Adaptation and recovery under stressful or traumatic…Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…Abstract Number: 1294 • ACR Convergence 2023
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…Abstract Number: 2024 • ACR Convergence 2023
Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials
Background/Purpose: Lupus nephritis (LN) is a severe and common (50%) organ-threatening manifestation of systemic lupus erythematosus and is associated with a high risk of progression…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 43
- Next Page »